J&J Duragesic Pediatric Exclusivity Blocks Mylan Generic Until January
Executive Summary
Mylan's generic fentanyl transdermal patch is blocked from launching before January 2005 by J&J/Alza's six-month pediatric exclusivity on Duragesic, FDA said
You may also be interested in...
Mylan Duragesic Generic Launches Into “Irrationally” Priced Market
Mylan's ability to recoup profits lost to early competitive pricing on Duragesic generics could depend on the timing of other ANDA approvals and Johnson & Johnson's ability to supply an "authorized" generic, CEO Robert Coury said Feb. 3
Mylan Duragesic Generic Launches Into “Irrationally” Priced Market
Mylan's ability to recoup profits lost to early competitive pricing on Duragesic generics could depend on the timing of other ANDA approvals and Johnson & Johnson's ability to supply an "authorized" generic, CEO Robert Coury said Feb. 3
FDA Decision On Mylan Duragesic ANDA Upheld By D.C. Court
FDA did not err in barring Mylan's transdermal fentanyl patch from coming to market until after Johnson & Johnson/Alza's pediatric exclusivity for Duragesic expires Jan. 23, a D.C. federal court said